Published • loading... • Updated
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Beta Bionics said its replay, press release and supplemental presentation will be posted online for investors reviewing second-quarter results.
Summary by mykxlg.com
4 Articles
4 Articles
Beta Bionics posts Q2 beats on 38% sales growth
The iLet bionic pancreas. [Image courtesy of Beta Bionics] Beta Bionics (Nasdaq:BBNX) today reported second-quarter financial results that topped the consensus estimates on Wall Street. Shares of BBNX remained unmoved at $15.17 apiece after the market closed today. The Irvine, California-based automated insulin delivery technology developer reported losses of $23.4 million in the quarter. That equals 53¢ per share on sales of $32 million for the…
Coverage Details
Total News Sources4
Leaning Left1Leaning Right1Center1Last UpdatedBias Distribution34% Left, 33% Center, 33% Right
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left
L 34%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
